Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment

November 6, 2015 12:00 PM EST

Cowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.

Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More

Acadia Pharma (ACAD) Tops Q3 EPS by 1c

November 5, 2015 4:13 PM EST

Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

... More